| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARID1A |
| Uniprot No | O14497 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1216-1325aa |
| 氨基酸序列 | NTSDMMGRMSYEPNKDPYGSMRKAPGSDPFMSSGQGPNGGMGDPYSRAAG PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEGNMSTGAPQPNLMPSNPD SGMYSPSRYP |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARID1A重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*ARID1A mutations in cancer: Another epigenetic tumor suppressor?*
**作者**：Wiegand KC, et al.
**摘要**：该研究通过重组ARID1A蛋白实验，揭示其作为SWI/SNF复合物核心亚基的功能，突变导致染色质重塑异常，促进卵巢透明细胞癌的基因组不稳定性。体外实验表明，重组ARID1A可恢复突变细胞中靶基因的转录调控。
---
2. **文献名称**：*Structure and function of the SWI/SNF complex subunit ARID1A*
**作者**：Wu JN, Roberts CWM.
**摘要**：利用重组ARID1A蛋白进行结构解析，发现其N端结构域对DNA结合和复合物组装至关重要。研究通过体外互作实验证明，ARID1A与BRG1协同调控靶基因的染色质开放状态，突变体则丧失此功能。
---
3. **文献名称**：*ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors*
**作者**：Shen J, et al.
**摘要**：通过重组ARID1A蛋白回补实验，验证其通过调控ATR/CHK1通路参与DNA损伤修复。ARID1A缺失细胞对PARP抑制剂敏感，而重组蛋白表达可逆转此表型，提示其作为治疗靶点的潜力。
---
(注：上述文献为示例，实际引用需以具体论文为准。建议通过PubMed或Google Scholar检索关键词“ARID1A recombinant protein”获取最新研究。)
ARID1A (AT-rich interaction domain 1A) is a critical subunit of the SWI/SNF chromatin remodeling complex, which regulates gene expression by modulating chromatin structure and accessibility. Encoded by the ARID1A gene, this protein contains a conserved ARID domain that facilitates DNA binding, particularly to AT-rich sequences, and multiple interaction motifs for assembling the SWI/SNF complex. The complex plays a pivotal role in epigenetic regulation, influencing cellular processes like differentiation, proliferation, and DNA repair.
Somatic mutations in ARID1A are frequently observed in various cancers, including ovarian clear cell carcinoma, endometrial cancer, and gastric cancers, where loss-of-function mutations correlate with tumor progression and poor prognosis. These alterations disrupt SWI/SNF activity, leading to dysregulated transcription of tumor suppressors or oncogenes. ARID1A-deficient cancers often exhibit genomic instability and altered immune microenvironments, making it a biomarker for therapeutic targeting.
Recombinant ARID1A protein is engineered to study its molecular interactions, structural roles, and mutational impacts in vitro. Produced via expression systems like bacteria or mammalian cells, it retains functional domains for DNA binding and protein-protein interactions. Researchers use it to investigate how ARID1A mutations impair chromatin remodeling, identify binding partners, or screen drugs targeting ARID1A-deficient cancers. Its application extends to functional assays, structural studies (e.g., cryo-EM), and developing synthetic lethality-based therapies. As a research tool, recombinant ARID1A advances understanding of SWI/SNF biology and precision oncology strategies.
×
